Page last updated: 2024-11-07

icrf 198

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ICRF 198: hydrolysis product of dexrazoxane; ADR-925 is the (S)-enantiomer of ICRF-198; structure given in first source; ADR 925 is identical to N,N'-((1S)-1-methyl-1,2-ethanediyl)-bis(N-(2-amino-2-oxoethyl))glycine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126521
MeSH IDM0166421

Synonyms (7)

Synonym
icrf 198
2-[(2-amino-2-oxoethyl)-[2-[(2-amino-2-oxoethyl)-(carboxymethyl)amino]propyl]amino]acetic acid
75459-34-6
adr 925
glycine, n,n'-(1-methyl-1,2-ethanediyl)bis(n-(2-amino-2-oxoethyl)-
icrf-198
2-[(2-amino-2-oxoethyl)-[(2s)-2-[(2-amino-2-oxoethyl)-(carboxymethyl)amino]propyl]amino]acetic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic analysis showed that pretreatment with dexrazoxane (100 mg/ kg) reduced the area under plasma concentration-time curve of doxorubicin, its mean residence time and plasma clearance significantly."( Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Boroujerdi, M; Vaidyanathan, S, 2000
)
0.31
" However, pharmacokinetic profile of both agents, particularly with respect to the cells and tissues essential for its action (cardiomyocytes/myocardium), remains poorly understood."( Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.
Brázdová, P; Bureš, J; Chládek, J; Jirkovská, A; Jirkovský, E; Karabanovich, G; Kovaříková, P; Lenčová, O; Pokorná, Z; Roh, J; Šimůnek, T; Stariat, J; Štěrba, M, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.76)18.7374
1990's10 (47.62)18.2507
2000's6 (28.57)29.6817
2010's4 (19.05)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.23 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]